167 related articles for article (PubMed ID: 12610519)
1. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
van Etten B; de Vries MR; van IJken MG; Lans TE; Guetens G; Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Br J Cancer; 2003 Jan; 88(2):314-9. PubMed ID: 12610519
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
[TBL] [Abstract][Full Text] [Related]
3. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
Nooijen PT; Manusama ER; Eggermont AM; Schalkwijk L; Stavast J; Marquet RL; de Waal RM; Ruiter DJ
Br J Cancer; 1996 Dec; 74(12):1908-15. PubMed ID: 8980389
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.
Seynhaeve AL; de Wilt JH; van Tiel ST; Eggermont AM; ten Hagen TL
Br J Cancer; 2002 Apr; 86(7):1174-9. PubMed ID: 11953868
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
de Wilt JH; ten Hagen TL; de Boeck G; van Tiel ST; de Bruijn EA; Eggermont AM
Br J Cancer; 2000 Mar; 82(5):1000-3. PubMed ID: 10737379
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat.
Manusama ER; Nooijen PT; Stavast J; Durante NM; Marquet RL; Eggermont AM
Br J Surg; 1996 Apr; 83(4):551-5. PubMed ID: 8665257
[TBL] [Abstract][Full Text] [Related]
8. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.
de Wilt JH; Manusama ER; van Tiel ST; van Ijken MG; ten Hagen TL; Eggermont AM
Br J Cancer; 1999 Apr; 80(1-2):161-6. PubMed ID: 10389992
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
[TBL] [Abstract][Full Text] [Related]
10. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach.
Manusama ER; Stavast J; Durante NM; Marquet RL; Eggermont AM
Eur J Surg Oncol; 1996 Apr; 22(2):152-7. PubMed ID: 8608832
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
de Wilt JH; Manusama ER; van Etten B; van Tiel ST; Jorna AS; Seynhaeve AL; ten Hagen TL; Eggermont AM
Br J Cancer; 2000 Nov; 83(9):1176-82. PubMed ID: 11027431
[TBL] [Abstract][Full Text] [Related]
14. Efficiency of recombinant human TNF in human cancer therapy.
Lejeune FJ; Liénard D; Matter M; Rüegg C
Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
[TBL] [Abstract][Full Text] [Related]
15. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
Borel Rinkes IH; de Vries MR; Jonker AM; Swaak TJ; Hack CE; Nooyen PT; Wiggers T; Eggermont AM
Br J Cancer; 1997; 75(10):1447-53. PubMed ID: 9166936
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
[TBL] [Abstract][Full Text] [Related]
17. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
De Vries MR; Borel Rinkes IH; Swaak AJ; Hack CE; Van De Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Eggermont AM
Eur J Clin Invest; 1999 Jun; 29(6):553-60. PubMed ID: 10354218
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases.
Brunstein F; Eggermont AM; de Wiel-Ambagtsheer Ga; van Tiel ST; Rens J; ten Hagen TL
Ann Surg Oncol; 2007 Feb; 14(2):795-801. PubMed ID: 17096052
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
[TBL] [Abstract][Full Text] [Related]
20. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM
Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
